Abstract
Germline genetics, gender and hormonal-signaling pathways are all well described modifiers of cancer risk and progression. Although an improved understanding of how germline genetic variants interact with other cancer risk factors may allow better prevention and treatment of human cancer, measuring and quantifying these interactions is challenging. In other areas of research, Information Theory has been used to quantitatively describe similar multivariate interactions. We implemented a novel information-theoretic analysis to measure the joint effect of a high frequency germline genetic variant of the p53 tumor suppressor pathway (MDM2 SNP309 T/G) and gender on clinical cancer phenotypes. This analysis quantitatively describes synergistic interactions among gender, the MDM2 SNP309 locus, and the age of onset of tumorigenesis in p53 mutation carriers. These results offer a molecular and genetic basis for the observed sexual dimorphism of cancer risk in p53 mutation carriers and a model is proposed that suggests a novel cancer prevention strategy for p53 mutation carriers.
Introduction
The p53 protein, frequently termed the "guardian of the genome," is a master regulator of cell cycle arrest and apoptosis. Individuals inheriting mutations in the TP53 gene (Li-Fraumeni syndrome) face a near-certain lifetime risk of cancer, yet the age of onset varies dramatically. While the MDM2 SNP309 variant and gender were known to influence this timing, their combined impact remained poorly quantified. This study utilizes Information Theory to explore whether these factors act independently or synergistically to accelerate tumorigenesis.
Methodology
Traditional statistical tools often struggle with the non-linear, complex interactions found in small clinical datasets. To address this, the authors employed an information-theoretic framework:
- Mutual Information ($I$): Used to quantify the statistical dependence between variables (e.g., genotype and age of onset) without assuming linearity.
- Synergistic Information ($S$): A metric used to determine the additional information provided by the interaction of two variables (gender and genotype) beyond their individual contributions.
- Optimal Binning: A principled approach was used to categorize the continuous variable of "age" into three discrete bins, maximizing the signal-to-noise ratio.
- Permutation Testing: Significance was determined using $10^6$ Monte Carlo iterations to account for small sample sizes.
The study analyzed 144 p53 mutation carriers from three international cohorts. To ensure results were not skewed by reproductive cancers, a sub-analysis was performed on 101 patients with non-gender-specific tumors, such as sarcomas and leukemias.
Key Results
The analysis confirmed a significant synergistic interaction between gender and the MDM2 SNP309 locus ($S = 0.06$ bits, $p=0.05$).
- Genotype Impact: The MDM2 SNP309 locus alone shared significant mutual information with the age of diagnosis (0.10 bits, $p=0.007$).
- Gender as a Modifier: Gender alone did not share significant mutual information with the age of diagnosis ($p=0.9$), suggesting it acts primarily as a modifier of the genetic variant's effect.
- Sexual Dimorphism in Acceleration: The G-allele of SNP309 acted as a potent accelerator in females, leading to an average onset age of 15 years compared to 31 years for the T-allele (a 16-year difference). In males, this effect was markedly attenuated (20 years for the G-allele vs. 30 years for the T-allele).
Discussion
These findings provide clinical weight to the "estrogen crosstalk" hypothesis. Previous biochemical studies showed that the G-allele of SNP309 increases MDM2 levels—a negative regulator of p53—and that estrogen further stimulates MDM2 transcription specifically from this allele. This creates a "double hit" in females, explaining the accelerated cancer onset.
Beyond the biological insights, this work demonstrates the utility of Information Theory in clinical genetics, particularly for rare diseases where sample sizes are limited. The study proposes that hormonal interventions might serve as a novel prevention strategy for high-risk female carriers, though this requires further clinical investigation.
Summary updated